KalVista Pharmaceuticals (KALV) EBT (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported EBT of -$57.9 million for Q3 2025, down 43.26% on a YoY basis from -$102.1 million in Q3 2024, and down 9.15% sequentially from -$53.1 million in Q2 2025.
KalVista Pharmaceuticals (KALV) EBT (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of EBT data on file, last reported at -$57.9 million in Q3 2025.
- For the quarter ending Q3 2025, EBT fell 43.26% year-over-year to -$57.9 million; the trailing twelve-month figure through Jul 2025 stood at -$203.5 million (down 157.26% YoY), and the FY2025 full-year result was -$180.1 million, down 241.91% from the prior year.
- EBT declined to -$57.9 million in Q3 2025, from -$53.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $29.3 million in Q2 2024 to a low of -$57.9 million in Q3 2025.
- A 5-year average of -$33.7 million and a median of -$37.6 million in 2022 frame the typical range for EBT.
- Across the five-year window, EBT soared 196.8% in 2024 and slumped 280.95% in 2025, its largest moves.
- Tracing KALV's EBT over 5 years: stood at -$33.3 million in 2021, then retreated by 11.62% to -$37.2 million in 2022, then fell by 4.7% to -$39.0 million in 2023, then plunged by 33.57% to -$52.1 million in 2024, then dropped by 11.29% to -$57.9 million in 2025.
- Business Quant data shows KALV's EBT at -$57.9 million in Q3 2025, -$53.1 million in Q2 2025, and -$52.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -57.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -57.94 Mn |
| Apr 30, 2025 | -53.08 Mn |
| Oct 31, 2024 | -52.06 Mn |
| Jul 31, 2024 | -40.44 Mn |
| Apr 30, 2024 | 29.33 Mn |
| Jan 31, 2024 | -29.03 Mn |
| Oct 31, 2023 | -38.98 Mn |
| Jul 31, 2023 | -38.84 Mn |
| Apr 30, 2023 | -30.30 Mn |
| Jan 31, 2023 | -37.40 Mn |
| Oct 31, 2022 | -37.23 Mn |
| Jul 31, 2022 | -38.11 Mn |
| Apr 30, 2022 | -57.36 Mn |
| Jan 31, 2022 | -37.86 Mn |
| Oct 31, 2021 | -33.35 Mn |
| Jul 31, 2021 | -22.09 Mn |
| Apr 30, 2021 | -19.37 Mn |
| Jan 31, 2021 | -13.05 Mn |
| Oct 31, 2020 | -13.28 Mn |
| Jul 31, 2020 | -14.78 Mn |